FindTrial
Sign In

Use of soluble human leukocyte antigen as marker of embryo quality for clinical outcomes in women undergoing IVF/ICSI cycles

Use of soluble human leukocyte antigen (sHLA-G) as potential biomarker of embryo quality for clinical outcomes in women undergoing IVF/ICSI non-donor cycles – A Prospective Observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067437
Enrollment
100
Registered
2024-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NIL: NIL

Sponsors

All India Institute of Medical Science
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: normo/hyper-responders, tubal factor, endometriosis, mild male factor infertility

Exclusion criteria

Exclusion criteria: oncofertility patients, donor recipient cycles, diminished ovarian reserve, male factor infertility,

Design outcomes

Primary

MeasureTime frame
Assessing influence of sHLA-G on Day-3 embryo qualityTimepoint: Day 3 Embryo quality—

Secondary

MeasureTime frame
Evaluating the quantitative analysis of sHLA-G in relation to the quality of embryos on Day 3, evaluating the quantitative analysis of sHLA-G in relation to the quality of embryos on Day 5, Evaluating the influence of sHLA-G on implantation rate, clinical pregnancy rate & on ongoing pregnancy rateTimepoint: Day 3 embryo quality, day 5 embryo quality, after 2weeks of embryo transfer, at 6weeks of pregnancy—

Countries

India

Contacts

Public ContactDr. Nisha

AIIMS,NEW DELHI

drneetasingh@gmail.com9818506855

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026